Serum Biomarkers for the Detection of Cardiac Dysfunction in Childhood Cancers Receiving Anthracycline-Based Treatment-Reference-Cited by-同舟云学术

Serum Biomarkers for the Detection of Cardiac Dysfunction in Childhood Cancers Receiving Anthracycline-Based Treatment

Published:2022-09-29 Issue:3 Volume:15 Page:1311-1321
ISSN:2456-2610
Container-title:Biomedical and Pharmacology Journal
language:en
Short-container-title:Biomed. Pharmacol. J.

Author:

Attina’ Giorgio¹,Triarico Silvia¹,Romano Alberto¹,Maurizi Palma¹,Mastrangelo Stefano¹,Ruggiero Antonio¹

Affiliation:

1. Pediatric Oncology Unit, Fondazione Policlinico Universitario A.Gemelli IRCCS, Universita’ Cattolica Sacro Cuore, Rome, Italy.

Abstract

Anthracyclines are routinely used in cancer chemotherapy in many childhood cancers. A serious adverse effect of doxorubicin chemotherapy is cardiotoxicity which may lead to congestive heart failure for long-term survivors years after treatment. Currently, echocardiography is used to control the heart function during anthracyclines therapy. B-type natriuretic peptide (BNP) and NT-proBNP as well as cardiac troponins have been proposed as clinical markers for subclinical anthracycline-induced cardiotoxicity. The BNP and pro-BNP can be easily measured in plasma and initial data indicate that the NT-proBNP could be sensitive predictor for the development of congestive heart failure.

Publisher

Oriental Scientific Publishing Company

Subject

Pharmacology

Reference94 articles.

1. Arcamone F, Cassinelli G, Fantini G, et al. Adriamycin, 14-hydroxydaunomycin, a new antitumor antibiotic from S. peucetius var. caesius. Biotechnol Bioeng 1969;11(6):1101-10.

2. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004;56(2):185-229.

3. Harris PA, Gross JF. Preliminary pharmacokinetic model for adriamycin (NSC- 123127). Cancer Chemother Rep 1975;59(4):819-25.

4. Sofia R, Melita V, De Vita A, et al. Cardiac Surveillance for Early Detection of Late Subclinical Cardiac Dysfunction in Childhood Cancer Survivors After Anthracycline Therapy. Front Oncol 2021;11:624057

5. Eksborg S, Strandler HS, Edsmyr F, Naslund I, Tahvanainen P. Pharmacokinetic study of i.v. infusions of adriamycin. Eur J Clin Pharmacol 1985;28(2):205-12.